Neushen Therapeutics Inc. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia, anxiety and post-traumatic stress disorder.

The Pacalis team is a blend of industry and academic expertise, led by co-founder and Monash university alumnus Dr David Bibby as Chief Executive Officer, and co-founder Professor Chris Langmead, ...

(NASDAQ:DRUG) is a biotechnology company that develops 5-HT2A and 5-HT2C serotonin receptor agonists to treat epilepsy, pain, depression, and PTSD. It leverages its proprietary platform to target ...

A study reveals distinct brain circuits that psychedelics activate to reduce anxiety without causing hallucinations in mice.

Longboard Pharmaceuticals has commenced the Phase III DEEp OCEAN Study of its investigational oral drug bexicaserin for ...

D2 and serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors. VRAYLAR forms two major metabolites, desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR), that have in ...

Mehmet Kadir Atdagi [Opens in a new window], Mehmet Gurkan Gurok [Opens in a new window] and Clozapine is an atypical antipsychotic crucial for treatment-resistant schizophrenia, characterised by its ...